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Abstract
Background: Although uncommon, mature small B- cell lymphomas may arise in the 
oral/maxillofacial area and oral pathologists must be aware of the key characteris-
tics of these neoplasms to perform an accurate diagnosis. In this manuscript, we at-
tempted to integrate the currently available data on the clinicopathological features 
of follicular lymphoma (FL), mantle cell lymphoma (MCL), extranodal marginal zone 
lymphoma of mucosa- associated lymphoid tissue (MALT- L), and chronic lymphocytic 
leukemia/ small lymphocytic lymphoma (CLL/SLL) affecting these anatomical regions.
Methods: An updated descriptive literature review was carried out and a detailed 
electronic search was done in multiple databases to gather all cases affecting the oral/
maxillofacial region and palatine tonsils.
Results: We observed that MALT- L was the most frequently reported subtype, fol-
lowed by FL, MCL, and CLL/SLL. The palate was affected in a high proportion of 
cases and the most usual clinical presentation was an asymptomatic swelling. MALT- L 
and CLL/SLL neoplastic cells were strongly associated with small salivary glands. FL 
showed no gender preference, while MCL and CLL/SLL were more prevalent in males 
and MALT- L in females. Overall, cases were more common in elderly individuals. 
Patients’ treatment and outcome varied, with MCL being the most aggressive neo-
plasm with a dismal prognosis in comparison to FL and MALT- L.
Conclusion: Despite the poor documentation in many of the cases available, espe-
cially regarding the microscopic and molecular features of tumors, this review demon-
strated that the oral mature small B- cell lymphomas investigated share similar clinical 
presentation, but carry different prognostic significance, demanding an accurate 
diagnosis.
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1  |  INTRODUC TION
Some mature B- cell lymphomas share a small- cell morphology, in-
cluding follicular lymphoma (FL), mantle cell lymphoma (MCL), ex-
tranodal marginal zone lymphoma of mucosa- associated lymphoid 
tissue (MALT- L), and chronic lymphocytic leukemia/ small lympho-
cytic lymphoma (CLL/SLL). In the oral/maxillofacial area, these le-
sions are not as common as large B- cell lymphomas, yet they may 
comprise an important number of cases, and for this reason, know-
ing the clinicopathological features of these neoplasms is important 
to allow an accurate diagnosis.
Herein, we aimed to provide an updated review of the main top-
ics of this heterogeneous group of neoplasms and to perform a de-
tailed electronic search for published reports of mature small B- cell 
lymphomas affecting the oral/maxillofacial region and the palatine 
tonsils. In order to homogenize our literature review, only cases pub-
lished from 2001 and that followed the World Health Organization 
guidelines for hematolymphoid neoplasms were considered.1 This 
study forms part of a special issue published by the Journal of Oral 
Pathology and Medicine covering the most important aspects of he-
matolymphoid lesions and neoplasms affecting the oral cavity and 
neighboring structures.
1.1  |  Lymphomagenesis of mature small B- 
cell lymphomas
FL is associated with a recurrent chromosomal translocation, t(14;18) 
(q32;q21), resulting in the fusion of the IGH and BCL2 genes. This 
occurs in early pre- B cells in the bone marrow that will further en-
gage in a process of re- entry into the GC and which may result in FL 
development (Figure 1).2 Meanwhile, MCL is associated with a recur-
rent t(11;14)(q13;q32) translocation, leading to Cyclin- D1 deregula-
tion. The event driving CCL/SLL is not fully understood, however, 
K E Y W O R D S
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F I G U R E  1  Schematic figure of mature 
small B- cell lymphomas development 
based on (A) early trigger event and 
(B) germinal center origin. Follicular 
lymphoma originates from a GC B cell; 
mantle cell lymphoma from a mantle 
zone B cell; marginal zone lymphomas 
from a marginal zone B cell; and chronic 
lymphocytic leukemia/ small lymphocytic 
lymphoma (CLL/SLL) have two possible 
origins: B cells that have not undergone 
GC differentiation or post- GC B cells. BM, 
bone marrow; CLL, chronic lymphocytic 
leukemia; FDC, follicular dendritic cell; 
GC, germinal center; MALT, mucosa- 
associated lymphoid tissue; SG, salivary 
gland; UM- CLL, unmutated CCL [Colour 
figure can be viewed at wileyonlinelibrary.
com]
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about 80% of patients with CLL/SLL carry at least one of the follow-
ing four chromosomal alterations: deletion in chromosome 13q14.3 
(del(13q)), del(11q), del(17p), or trisomy 12.3 Moreover, a later event 
is the mutation in the immunoglobulin heavy- chain variable region 
(IGHV) gene. CCL/SLL with mutated IGHV originates from post- GC 
B cells, while non- mutated cases are thought to originate from pre-
 GC (naive) B cells or GC- independent antigen- experienced B cells.4
MALT- L development is acknowledged to have a chronic anti-
gen stimulus, either of microbial origin or auto- antigens. The antigen 
does not directly transform the lymphoid cell, it rather increases the 
risk of lymphomatous transformation.1,5 The autoreactive B cells 
that progressively infiltrate salivary glands in Sjögren's Syndrome 
(SS) reproduce the architecture of mucosa- associated lymphoid tis-
sue.6,7 The risk of SS patients to develop a NHL is estimated to be 4- 
to 19- fold higher than the general population.6 Several independent 
predictors have been described, such as salivary gland enlargement, 
anti- Ro/La autoantibodies, ectopic germinal centers, among others.8
1.2  |  Follicular lymphoma
FL is the second most common subtype of non- Hodgkin lymphoma 
(NHL) in western countries.9,10 Within the oral cavity, this frequency 
pattern seems to be maintained.11- 14 In our review, we retrieved in-
formation of 22 cases of oral/maxillofacial FL with enough demo-
graphic or clinic- pathologic data (Table S1). We observed a male: 
female ratio of 1.2:1 and a mean age at diagnosis of 67 years (ranging 
from 38 to 92 years) (Table 1), in line with the overall literature.9
The palate (n = 14) and gingiva (n = 3) were the most affected oral 
sites (Table 1) usually demonstrating a localized swelling as the most 
frequent clinical appearance. The most common manifestation of FL 
is a widespread disease without B symptoms.1,2 Four cases reported 
simultaneous involvement of lymph nodes and one reported wide-
spread bone marrow involvement. No description of B symptoms 
was identified. Only eight cases described the Ann Arbor stage. 
Early stage disease was reported in 50% of cases, contrasting with 
the overall tendency of FL, which is about 10– 25% of patients with 
early stage disease.1,15 According to the last WHO classification,1 
grading of FL should be performed according to the Lugano classifi-
cation, in which the designation of a case as A or B (asymptomatic or 
symptomatic) is no longer required.
Microscopically, FL is characterized by a predominant follicu-
lar growth pattern, but a partial or complete absence of a follicular 
pattern might also be encountered, especially in small biopsies. The 
classical appearance is of closely packed, spread follicles, effacing 
the normal architecture of the affected tissue. The neoplastic folli-
cles are poorly defined, with attenuated or absent mantle zones, and 
lack of polarization (Figure 2A). A monomorphic cellular phenotype 
is observed, with a predominance of centrocytes, and scattered cen-
troblasts.1,2,16 FL grading is performed based on the number of cen-
troblasts per high- power field: Grade 1 (0– 5); Grade 2 (6– 15); Grade 
3A (>15); and Grade 3B (>15 with solid sheets of centroblasts pres-
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in Grade 3B cases.17 In our review, 14 cases reported the histological 
grade: eight were grade 1, four were grade 2, and only two cases 
were graded as 3, in line with the literature.1
Four architectural patterns are recognized: follicular (>75% of 
follicular architecture); follicular and diffuse (25– 75% of follicular 
architecture); focally follicular / predominantly diffuse (<25% of fol-
licular architecture); diffuse (absence of follicular areas, but micro-
follicles remain present).1 We did not identify any description of such 
patterns in the oral cavity cases.
FL immunophenotype is usually of CD20+, CD10+, BCL6+, 
BCL2+, CD23+/−, CD43−, CD5−, Cyclin D1− (Table 2).1,16 CD10 
expression is typically stronger inside the neo- follicles compared 
to the interfollicular area (Figure 2B). Bcl2 expression, a result of 
t(14;18)(q32;q21), is useful to rule out reactive follicular hyperpla-
sia (Figure 2C).1 Fluorescence in situ hybridization (FISH) is the most 
sensitive method to detect the fusion gene. In the cases reviewed, 
seven were shown to be positive for the translocation, whereas five 
were negative and 11 did not perform/present the translocation sta-
tus. As a low- grade tumor, Ki67 in FL is usually low, around 20% for 
grade 1 and 2 tumors.18
FL is known to regress and relapse over the years, requiring pa-
tients’ careful surveillance and possible maintenance of their ther-
apy.2 In our review, only two patients presented recurrence during 
follow- up and no patient deceased due to the tumor.
1.3  |  Mantle cell lymphoma
MCL represents 1.3% of all hematological malignancies.10 
However, a US- population- based study observed that oropharyn-
geal MCL accounted for 7.8% of the cases.14 Likewise, a study of 
oral NHL found that MCL was the third most common type.11 We 
identified 21 published cases of oral/maxillofacial MCL (Table S1). 
The male: female ratio was 4.2:1, in agreement with general lit-
erature.9 The average age at diagnosis was 69.95 years (range 41– 
93), which is slightly lower than the overall reported of 72.9 years 
(Table 1).10
The most common clinical presentation was a non- ulcerated 
swelling usually in the palate (n = 15). Cases concomitantly affect-
ing the palate and other oral sites were also identified. Five patients 
(20%) presented with bilateral palatal swelling and 11 patients (52%) 
were diagnosed with widespread disease. Only one study reported 
a history of fever, while other systemic symptoms included nausea, 
loss of appetite, and abdominal pain (Table S1). Information about 
the stage was available for six cases: Four patients were diagnosed 
in advanced stages (III/IV) (Table 1), which seems to corroborate the 
literature.1
MCL is classified into four major morphological variants: leu-
kemic non- nodal, classic, blastoid, and pleomorphic. The WHO 
also recognizes small- cell and marginal- zone- like variants.1 We 
F I G U R E  2  Microscopic and immunohistochemical features of follicular lymphoma (A- C) and mantle cell lymphoma (D- F). (A): Irregular, 
large neoplastic follicle, without the presence of tingible- body macrophages and the so- called “starry sky pattern.” Loss of polarization 
between the follicular margins is also observed (hematoxylin– eosin, ×100). (B): Diffuse expression of CD10 antibody in the neoplastic 
cells (diaminobenzidine, ×100). (C): Remarkable expression of Bcl- 2 antibody in the central areas of the neoplastic follicles which were also 
positive to CD10 (diaminobenzidine, ×100). (D): Microscopic aspect of classic mantle cell lymphoma, showing a sheet of small- sized cells 
with scant cytoplasm and condensed nuclei (hematoxylin– Eosin, ×200). (E): Representative case of pleomorphic variant with large cells, pale 
cytoplasm and vesicular nuclei (hematoxylin– eosin, ×200). (F): Diffuse expression of cyclin- D1 in the classic variant of mantle cell lymphoma 
(diaminobenzidine, x200) [Colour figure can be viewed at wileyonlinelibrary.com]
(A) (B) (C)
(D) (E) (F)
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identified the classic variant as the most common (n = 11), fol-
lowed by the blastoid (n = 3), small- cell (n = 1), and pleomorphic 
(n = 1).19
In classic MCL, the neoplastic cells are small to medium- size with 
moderately irregular nuclear contours. The chromatin is rather dis-
persed, nucleoli are inconspicuous, and cytoplasm scant (Figure 2D). 
Hyaline small vessels and epithelioid histiocytes are commonly ob-
served and non- neoplastic reactive plasma cells may also be pres-
ent. The number of mitotic figures is usually low to moderate.1,20 
The architectural pattern of classic MCL varies between diffuse, 
vague nodules, interstitial, mantle zone growth, and even follicu-
lar.21 In the blastoid variant, malignant cells resemble lymphoblasts, 
being slightly larger with dispersed chromatin and the mitotic rate 
is considerably higher than classic MCL.1 The pleomorphic variant 
presents large cells, with a round to oval nuclear contours, and pale 
cytoplasm (Figure 2E). The small- cell variant comprises small and 
round lymphomatous cells with compacted chromatin. The marginal- 
zone- like subtype exhibit foci of cells with abundant pale cytoplasm, 
resembling monocytoid cells.
Neoplastic cells present strong reactivity to CD20, and the 
Bcl2+, CD10– and Bcl6– phenotype helps to differentiate MCL from 
FL.20 Residual GC cells (CD10+, Bcl6+) can be detected admixed 
with the neoplastic population. CD5 and Cyclin- D1 (Figure 2F) are 
important markers for MCL diagnosis (Table 2). In view of possible 
CD5 or Cyclin- D1 negativity, SOX11 has emerged as a marker to as-
sist MCL diagnosis.22 We retrieved two oral cases lacking CD5 ex-
pression (Table S1). Classic and small- cell variants have considerably 
lower proliferation index, around 15%, compared to pleomorphic 
and blastoid variants (~28%), and the percentage of Ki67- positive 
cells may be associated with overall survival.23
Cytogenetics typically reveals the translocation t(11;14)(q13; 
q32) in the vast majority (90%) of MCL cases, but with no prognostic 
impact.24 The small percentage of Cyclin- D1- negative cases usually 
presents cyclin D2/cyclin D3 translocations. We found six positive 
cases for t(11;14)(q13;q32) or CCND1 rearrangement, however, 
most of the reports did not describe this information.
MCL is recognized as an aggressive lymphoma with poor re-
sponse to conventional therapy.25 Recurrences were described in 
three cases, while the status during follow- up was provided for 15 
patients, in which seven were alive, five were deceased due to the 
tumor, and three were deceased due to unknown causes.
1.4  |  Extranodal marginal zone lymphoma of 
mucosa- associated lymphoid tissue
MALT- L is the fourth most common type of NHL in the oro-
pharyngeal region, representing 5.3% of all lymphoid malignan-
cies in a population- based study conducted in the United States.14 
Interestingly, MALT- L represents the most common type of NHL af-
fecting the salivary glands,26 most likely as a result of its association 
with SS. In our literature review, 60 cases of MALT- L in the oral/
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was 1:2, indicating that women are more commonly affected by oral 
MALT- L. The mean age at diagnosis was 56.9 years, ranging from 7 to 
87 years (Table 1), corroborating with the general literature on this 
tumor.1,27 Among 39 oral/maxillofacial cases with available informa-
tion, 10 patients (25.6%) had SS.
The most common site of oral MALT- L was the lip (n = 17). In 
four cases, the site of origin was described as minor salivary glands, 
without no further specification. Other common locations included 
the palate, buccal mucosa, and palatine tonsils. The majority of pa-
tients presented a localized swelling, with five patients also showing 
ulcerated areas. No case reporting B symptoms was found. Only 22 
cases reported stage at diagnosis, with 21 cases at initial stages (I/
II). Advanced stages represented 4.5% (Table 1), which is lower than 
in major salivary glands, where 23% of cases were previously diag-
nosed in stages III or IV.28
MALT- L is microscopically characterized by the proliferation of 
monoclonal small to medium- sized cells resembling centrocytes, 
with irregular nuclei, dispersed chromatin and inconspicuous nucle-
oli, or with a monocytoid appearance (Figure 3A).1 Neoplastic cells 
gradually replace the mixed inflammatory infiltrate present at the 
site, while the salivary duct structures persist as epimyoepithelial 
islands.29 Three or more aggregates of marginal zone cells might in-
filtrate the epithelial structures, resulting in lymphoepithelial lesions 
(LEL),1 which may occur both in a reactive or neoplastic context.30 
A halo- like expansion of centrocyte- like or monocytoid B cells 
around the LEL is recognized as a morphologic feature suggestive 
of an initial/emerging MALT- L.31 The presence of amyloid can also 
be observed in MALT- L, and we identified one report describing an 
amyloid- rich minor salivary gland case (Supplementary Table S1).32 
When solid, sheet- like, or clusters proliferations (>20 cells) of trans-
formed large cells are present, the tumor should rather be diagnosed 
as DLBCL.1 A high number of plasma cells in some cases may simu-
late extramedullary plasmacytomas.
MALT- L neoplastic cells are usually CD20+, CD79a+, CD5- , 
CD10- , CD23- , and CD43+/- (Table 2, Figure 3B).1 This pheno-
type is virtually identical to non- neoplastic marginal- zone B cells, 
thus a clonality evaluation is recommended.31 Typically, all neo-
plastic cells present with identical immunoglobulin heavy- chain 
IgH rearrangements, combined with the expression of a single 
immunoglobulin light- chain (IgL) restriction, although in the liter-
ature kappa/lambda restriction is not demonstrated in all cases 
by immunohistochemistry. During the multistep antigen- driven 
lymphomagenesis, lymphoid cell proliferation is thought to prog-
ress first to monoclonality and then, after gaining secondary ge-
netic alterations, to MALT- L.33 Thus, limited areas of monoclonal 
cells are associated with a borderline diagnosis between clonal 
LESA/MESA or MALT- L.34 Conversely, as malignant transforma-
tion might occur in a particular location within the lesion, areas 
of polyclonal cells can persist in other zones and this should not 
eliminate the possibility of MALT- L.7 Recognition of the cellular 
F I G U R E  3  Microscopic findings and immunophenotype of MALT lymphoma (A- C) and chronic lymphocytic leukemia / small 
lymphocytic lymphoma (D- F). (A): Small and medium cells with a prominent monocytoid appearance. Reminiscent salivary ducts are also 
visualized (hematoxylin- eosin, ×400). (B): Diffuse expression of CD20 antibody demonstrating the B- cell phenotype of MALT lymphoma 
(diaminobenzidine, x200). (C): Pan- cytokeratin (AE1/AE3) marker highlighting scattered salivary gland structures in contrast with the sheet 
of neoplastic cells (diaminobenzidine, ×200). (D): Small and medium cells with clumped chromatin admixed with larger cells with dispersed 
chromatin (hematoxylin– eosin, ×400). (E): Diffuse expression of CD5 antibody in the neoplastic cells (diaminobenzidine, ×400). (F): Diffuse 
expression of CD23 antibody in the neoplastic cells (diaminobenzidine, ×400) [Colour figure can be viewed at wileyonlinelibrary.com]
(A) (B) (C)
(D) (E) (F)
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immunophenotype might contribute in this regard as a higher 
number of CD3- positive cells would favor the diagnosis of a reac-
tive lesion.29,30 In our review, the percentage of Ki67- positive cells 
in oral cases ranged from 5% to 30%.35,36
MALT- L is recognized as a low- grade neoplasm. We observed 
that six patients (20.6%) presented with disease relapse: one at 
the same site (buccal mucosa), one in multiple oral sites, one in the 
lungs, and one in the gastric mucosa (Table S1). Localized low- grade 
MALT- L of the oral cavity and major salivary glands are usually ex-
cised and may not require any additional treatment besides an active 
monitoring.37 We found that only three patients deceased during 
follow- up (in a mean time of 47 months).
1.5  |  Chronic lymphocytic leukemia/small 
lymphocytic lymphoma
The WHO recognizes CLL and SLL as the same disease, which only dif-
fers according to the spread/location. CLL is characterized by a mono-
clonal B- cell count >5 × 109/L in the peripheral blood. The term SLL is 
used for cases with a cell count of less than 5 × 109/L with extramedul-
lary involvement1 which is rare, and occurs most commonly in the skin 
or the central nervous system.38 Sixteen cases of oral/maxillofacial 
CLL/SLL cases were retrieved from the literature— 15 (93%) consisted 
of CLL and one was diagnosed as SLL (7%). We also found four articles 
describing the Richter's Syndrome (RS), a sudden transformation of 
CLL/SLL into a high- grade large- cell lymphoma (Table S1).39
The male: female ratio was 4.3:1 (Table 1), in contrast with other 
studies that reported ratios of 1.88:1.9,10 The mean age at diagnosis 
was 63.9 years, similar to the 62- year mean age of extramedullary 
cases.38 Five cases involved the minor salivary glands, although the 
exact oral site was not determined (Table 1). The most common clin-
ical manifestation was swelling, and local symptoms included pain, 
dysphasia, and epistaxis (Table S1). Seven patients presented wide-
spread involvement, most commonly to the lymph nodes. Only one 
case reported fever.
CLL is usually staged according to the Rai or Binet systems, while 
SLL is staged using the Ann Arbor staging scheme. In the context of 
CLL, Rai and Binet systems have higher prognostic value and thus 
are recommended.3 In our review, only two cases reported the stage 
based on these systems (Rai— 0 and Binet— C), while eight patients 
were classified according to the Ann Arbor stage (Table 1).
Extranodal involvement of CLL or SLL is characterized by a vaguely 
nodular or sheet- like monotonous infiltrate of neoplastic cells with a 
round nucleus, condensed chromatin, and scant to moderate cytoplasm 
(Figure 3D).40 The clumped chromatin is described as having a “soccer 
ball- like” or “block- like” appearance.41,42 Larger cells— prolymphocytes 
and paraimmunoblasts— can be found admixed in the background of 
small cells, and have clumped or dispersed chromatin, a single central 
nucleolus, and more abundant cytoplasm.41
CLL is characterized by the expansion of CD5+CD23+ monoclo-
nal mature CD20+ B cells in the peripheral blood, secondary lymphoid 
tissues and bone marrow. In tissue samples, the co- expression of CD5 
and CD23 in mature B cells is useful to confirm the diagnosis of CLL/
SLL (Table 2, Figure 3E- F).1,3 CyclinD1/SOX11 negativity and CD200 
positivity rules out the diagnosis of MCL.3 Ki67 expression is variable: 
it can range from 2% to 30– 40%,43,44 but is usually below 50%.
CLL/SLL has no specific genetic signature.1 IGHV gene status 
seems to have a prognostic value and is also associated with the 
stage of cell origin at the GC. It is estimated that 50– 70% of CLL have 
mutated- IGHV (post- GC B cell origin) and 30– 50% unmutated (pre- GC 
B- cell origin).1 In our review, no report described the IGHV status.
The clinical outcome can vary from a very indolent clinical course 
with no need for treatment, to rapidly progression associated with 
death due to therapy- related and/or disease- related complications.3 
In oral cases, one patient was managed with a “wait and watch” ap-
proach, and seven patients received chemotherapy. One patient de-
ceased due to disease progression and another due to secondary 
infection. Ten patients were alive at the time of publication, but the 
follow- up period was short (12– 18 months).
An aggressive form of disease progression is the RS, which can 
occur in either a DLBCL or a Hodgkin lymphoma.39 In our review, 
all four cases that documented RS progressed to DLBCL. Three pa-
tients (75%) were females, with a mean age of 58.7 years. In all cases, 
the lesion affected the jawbones associated mucosa. Two patients 
deceased during follow- up, confirming the aggressive nature of this 
condition.
2  |  CONCLUSIONS
Our literature review has compiled the available data of the main ma-
ture small B- cell lymphomas affecting the oral/maxillofacial region. 
We observed a significant amount of missing data, with a particular 
lack of immunophenotyping and genetic information, key features 
for an accurate diagnosis. SS status (for MALT- L cases), microscopic 
features, and follow- up data were also poorly described. Based on 
the limitations we faced for data analysis, our suggestions for future 
reports of mature small B- cell lymphomas in the oral/maxillofacial 
region are:
• Continue reporting new cases with full information, preferably 
with follow- up information;
• Ensure precise recording of all relevant demographic and clinical 
data, including the precise primary site;
• Include full information on microscopic analysis (subtype/grade) 
and immunophenotyping;
• Perform genetic analysis if possible
a. t(14;18)(q32;q21) investigation in FL cases
b. t(11;14)(q13;q32) investigation in MCL cases
c. IGHV gene status in CLL/SLL and MALT- L cases
• Report the Sjögren's syndrome status in MALT- L cases;
• Report CLL clinical stage following the Rai or Binet systems;
• If reporting a case series that contains mature small B- cell lym-
phomas, include full information about each case (in supplemen-
tary material if necessary).
    |  629WAGNER Et Al.
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